Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities by Peter N. Morcos, Junyi Li, Iraj Hosseini, Chi‐Chung Li

Connect to this object online.

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase-positive non‐small cell lung cancer by Joy C. Hsu, Felix Jaminion, Elena Guerini, Bogdana Balas, Walter Bordogna, Peter N. Morcos, Nicolas Frey

Connect to this object online.

Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab by Peter N. Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Dirk Garmann

Connect to this object online.

Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor by Mario González‐Sales, Ashley L. Lennox, Fei Huang, Chandra Pamulapati, Ying Wan, Libo Sun, Tymara Berry, Melissa Kelly Behrs, Faye Feller, Peter N. Morcos

Connect to this object online.

Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science by Ashley L. Lennox, Fei Huang, Melissa Kelly Behrs, Mario González‐Sales, Neha Bhise, Ying Wan, Libo Sun, Tymara Berry, Faye Feller, Peter N. Morcos

Connect to this object online.

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors by Peter N. Morcos, Jan Schlender, Rolf Burghaus, Jonathan Moss, Adam Lloyd, Barrett H. Childs, Margaret E. Macy, Joel M. Reid, John Chung, Dirk Garmann

Connect to this object online.